Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis

OBJECTIVES: On July 20, 2012, the European Medicines Agency (EMA) provided a recommendation that limits the long-term use of calcitonin. Based on this recommendation, we investigate the presence or absence of a cancer diagnosis in subjects who participated in the ongoing clinical trial of elcatonin....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Osteoporos Sarcopenia
Autors principals: Okamoto, Hiroaki, Shibazaki, Nayumi, Yoshimura, Takeshi, Uzawa, Toyonobu, Sugimoto, Toshitsugu
Format: Artigo
Idioma:Inglês
Publicat: Korean Society of Osteoporosis 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7093680/
https://ncbi.nlm.nih.gov/pubmed/32226828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2020.02.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars